1. Introduction to BCMA Targeting Therapy
1.1 Overview
1.2 History of BCMA Targeting Therapeutics

2. BCMA Targeting Therapeutics Mechanism of Action

3. BCMA As Ideal Target for Hematological Cancer

4. Global BCMA Targeting Drugs Market Analysis
4.1 Overview
4.2 Future Opportunity

5. Global BCMA Targeting Drugs Market Opportunity by Region
5.1 US
5.2 Europe
5.3 Japan
5.4 Rest of World

6. Global BCMA Targeting Drugs Market by Cancer Type
6.1 Multiple Myeloma
6.2 Lymphoma
6.3 Leukemia

7. Blenrep (Belantamab Mafodotin-blmf) - First Approved BCMA Targeting Therapy
7.1 Overview
7.2 Dosage & Price Analysis
7.3 Sales Analysis

8. Abecma (Idecabtagene Vicleucel) - Second Approved BCMA Targeting Therapy
8.1 Overview
8.2 Dosage, Price & Sales Analysis

9. BCMA Targeting Drugs Sales Forecast 2026
9.1 Blenrep
9.2 Abecma

10. BCMA Targeting Drugs Clinical Trials Insight
10.1 By Phase
10.2 By Development Status
10.3 By Region

11. BCMA Targeting Drugs Market - Ongoing Research & Development
11.1 Ciltacabtagene Autoleucel (JNJ-68284528)
11.2 Allo715
11.3 CTX120
11.4 C-CAR088
11.5 CT053
11.6 HPN217
11.7 Pacanalotamab (AMG 420/ BI 836909)
11.8 PHE 885
11.9 bb21217
11.10 SEA BCMA

12. Global BCMA Targeted Drugs Clinical Trials Insight
12.1 Research
12.2 Preclinical
12.3 Clinical
12.4 Phase-0
12.5 Phase-I
12.6 Phase-I/II
12.7 Phase-II
12.8 Phase-II/III
12.9 Phase-III
12.10 Preregistration

13. Approved BCMA Targeted Drugs Clinical Insoght
13.1 Belantamab Mafodotin - GlaxoSmithKline
13.2 Idecabtagene Vicleucel - Bluebird Bio/Celgene Corporation

14. Global BCMA Targeting Drug Market Dynamics
14.1 Market Drivers
14.2 Market Challenges

15. Global BCMA Targeting Drug Market Future Outlook

16. Competitive Landscape
16.1 Allogene Therapeutics
16.2 AbbVie
16.3 Amgen
16.4 BioTherapeutics
16.5 Bluebird Bio
16.6 Bristol Mayer Squibb
16.7 Carsgen Therapeutics
16.8 Celgene
16.9 Cogent Bioscience
16.10 CRISPR Therapeutics
16.11 GlaxoSmithKline
16.12 Harpoon Therapeutics
16.13 Hrain Biotechnology
16.14 iCell Gene Therapeutics
16.15 Johnson & Johnson
16.16 Juno Therapeutics
16.17 Novartis
16.18 Poseida Therapeutics
16.19 Seagen
16.20 Seattle Genetics

List of Figures

Figure 1-1: Evolution of BCMA Targeting Therapeutics

Figure 2-1: BCMA Signaling Pathways
Figure 2-2: BCMA Targeting Therapeutics - Mechanism of Action
Figure 2-3: Blenrep - Mechanism of Action
Figure 2-4: Abecma - Mechanism of Action

Figure 3-1: Role of BCMA in Cell Cycle Signaling Pathway Regulation
Figure 3-2: Strategies For Targeting BCMA
Figure 3-3: Role of BCMA in Cancer

Figure 4-1: Global - Newly Diagnosed Leukemia Cases, 2020 - 2026
Figure 4-2: Global - Newly Diagnosed Hodgkin's Lymphoma Cases, 2020 - 2026
Figure 4-3: Global - Newly Diagnosed Non-Hodgkin's Lymphoma Cases, 2020 - 2026
Figure 4-4: Global - Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
Figure 4-5: Global - BCMA Targeting Therapy, Blood Cancer Therapeutics & Multiple Myeloma Therapeutics Market (US$ Billion), 2020
Figure 4-6: Global - BCMA Targeting Therapy Market Opportunity (US$ Million), 2020-2026
Figure 4-7: Global - Blood Cancer Drug Market Opportunity (US$ Billion), 2020-2026
Figure 4-8: Global - Multiple Myeloma Drug Market Opportunity (US$ Billion), 2020-2026
Figure 4-9: Global - BCMA Targeting Therapy Market by Product (%) 2026

Figure 5-1: US - Newly Diagnosed Leukemia Cases, 2020 - 2026
Figure 5-2: US - Newly Diagnosed Hodgkin's Lymphoma Cases, 2020 - 2026
Figure 5-3: US - Newly Diagnosed Non-Hodgkin's Lymphoma Cases, 2020 - 2026
Figure 5-4: US - Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
Figure 5-5: US - BCMA Targeting Therapy Market Opportunity (US$ Million), 2020-2026
Figure 5-6: US - BCMA Targeting Therapy Market by Product (%), 2026
Figure 5-7: Europe - Newly Diagnosed Leukemia Cases, 2020 - 2026
Figure 5-8: Europe - Newly Diagnosed Non-Hodgkin's Lymphoma Cases, 2020 - 2026

Figure 5-9: Europe - Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
Figure 5-10: Europe - BCMA Targeting Therapy Market Opportunity (US$ Million), 2020-2026
Figure 5-11: Europe - BCMA Targeting Therapy Market by Product (%), 2026
Figure 5-12: Japan - Newly Diagnosed Leukemia Cases, 2020 - 2026
Figure 5-13: Japan - Newly Diagnosed Hodgkin's Lymphoma Cases, 2020 - 2026
Figure 5-14: Japan - Newly Diagnosed Non-Hodgkin's Lymphoma Cases, 2020 - 2026
Figure 5-15: Japan - Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
Figure 5-16: Japan - BCMA Targeting Therapy Market Opportunity (US$ Million), 2022-2026
Figure 5-17: Japan - BCMA Targeting Therapy Market by Product (%), 2026
Figure 5-18: ROW - BCMA Targeting Therapy Market Opportunity (US$ Million), 2021 -2026
Figure 5-19: ROW - BCMA Targeting Therapy Market by Product (%), 2026
Figure 5-20: ROW - BCMA Targeting Therapy Market Share by Countries (%), 2026

Figure 6-1: Global - Number of Multiple Myeloma Cases, 2021-2026
Figure 6-2: Global - Multiple Myeloma Targeting BCMA Targeting Therapeutics Market Oportunity (US$ Million), 2021 - 2026
Figure 6-3: Global - Number of NHL Cases, 2021-2026
Figure 6-4: Global - Number of Hodgkin's Lymphoma Cases, 2021-2026
Figure 6-5: Global - BCMA Targeting Therapeutics Market Opportunity in Lymphoma (US$ Million), 2025 & 2026
Figure 6-6: Global - Number of Newly Diagnosed Leukemia Cases, 2021-2026
Figure 6-7: Global - BCMA Targeting Therapeutics Market Opportunity in Leukemia (US$ Million), 2025 & 2026

Figure 7-1: US - Blenrep FDA Approval & Orphan Designation Year
Figure 7-2: Europe - Blenrep EMA Approval & Orphan Designation Year
Figure 7-3: US - Price for 100mg Supply & Price for Single Treatment Cycle using Blenrep (US$), November'2021
Figure 7-4: Europe - Price for 100mg Supply & Price for Single Treatment Cycle using Blenrep (GBP), November'2021
Figure 7-5: Blenrep - Initial & Reduced Dose (mg/kg/3 Week)
Figure 7-6: Global - Blenrep Quarterly Sales Value (US$/GBP Million), Q1 - Q3, 2021
Figure 7-7: US - Blenrep Quarterly Sales Value (US$/GBP Million), Q1 - Q3, 2021

Figure 7-8: Europe - Blenrep Quarterly Sales Value (US$/GBP Million), Q1 - Q3, 2021
Figure 7-9: Global - Blenrep Sales Value by Region (US$/GBP Million), H1 2021
Figure 7-10: Global - Blenrep Half Yearly Sales Share by Region (%), H1 2021
Figure 7-11: Global - Blenrep Quarterly Sales Value by Region (US$/GBP Million), Q3, 2021
Figure 7-12: Global - Blenrep Quarterly Yearly Sales Share by Region (%), Q3, 2021
Figure 7-13: Global - Blenrep Quarterly Sales Value (US$/GBP Million), Q3 & Q4, 2020
Figure 7-14: US - Blenrep Quarter Sales Value (US$/GBP Million), Q3 & Q4, 2020
Figure 7-15: Europe - Blenrep Quarter Sales Value (US$/GBP Million), Q3 & Q4, 2020
Figure 7-16: Global - Blenrep Annual Sales Value by Region (US$/GBP Million), 2020
Figure 7-17: Global - Blenrep Sales Share in by Region (%), 2020

Figure 8-1: US - Abecma FDA Approval & Orphan Designation Year
Figure 8-2: Europe - Abecma EMA Approval & Orphan Designation Year
Figure 8 3: Abecma - Minimum & Maximum Dosage of CAR Positive Viable T Cells (Million ells), November'2021
Figure 8-4: Global - Abecma Quarterly Sales Value (US$ Million), Q2 & Q3, 2021

Figure 9-1: Global - Blenrep Sales Forecast (US$ Million), 2021 - 2026
Figure 9-2: US - Blenrep Sales Forecast (US$ Million), 2021 - 2026
Figure 9-3: Europe - Blenrep Sales Forecast (US$ Million), 2022 - 2026
Figure 9-4: Japan - Blenrep Sales Forecast (US$ Million), 2022 - 2026
Figure 9-5: ROW - Blenrep Sales Forecast (US$ Million), 2022 - 2026
Figure 9-6: Global - Abecma Sales Forecast (US$ Million), 2021 - 2026
Figure 9-7: US - Abecma Sales Forecast (US$ Million), 2021 - 2026
Figure 9-8: Europe - Abecma Sales Forecast (US$ Million), 2022 - 2026
Figure 9-9: Japan - Abecma Sales Forecast (US$ Million), 2022 - 2026
Figure 9-10: ROW - Abecma Sales Forecast (US$ Million), 2022 - 2026

Figure 10-1: Global - Number of BCMA Related Clinical Trials by Phase, November'2021
Figure 10-2: Global - BCMA Related Clinical Trials by Phase, November'2021
Figure 10-3: Global - Number of BCMA Related Clinical Trials by Development Status, November'2021


Figure 10-4: Global - Number of BCMA Related Clinical Trials by Development Status (%), November'2021
Figure 10-5: Global - Number of BCMA Related Clinical Trials by Region, November'2021

Figure 11-1: Investigational BCMA Targeting Therapeutics
Figure 11-2: CARTITUDE 1 Trial - Study Initiation & Completion Year
Figure 11-3: CARTITUDE 2 Trial - Study Initiation & Completion Year
Figure 11-4: CARTITUDE 4 Trial - Study Initiation & Completion Year
Figure 11-5: ALLO715 Phase I Trial - Study Initiation & Completion Year
Figure 11-6: CTX120 Phase I Trial - Study Initiation & Completion Year
Figure 11-7: C CAR088 Phase I Trial - Study Initiation & Completion Year
Figure 11-8: CT053 Phase II Trial - Study Initiation & Completion Year
Figure 11-9: CT053 Phase I Trial - Study Initiation & Completion Year
Figure 11-10: HPN217 Phase I Trial - Study Initiation & Completion Year
Figure 11-11: AMG 420 Phase I Trial - Study Initiation & Completion Year
Figure 11-12: PHE 885 Phase I Trial - Study Initiation & Completion Year
Figure 11-13: bb21217 Phase I Trial - Study Initiation & Completion Year
Figure 11-14: SEA BCMA Phase I Trial - Study Initiation & Completion Year

Figure 12-1: Global - number of BCMA Targeted Drug in Clinical trials, 2021 -2026

Figure 14-1: Global BCMA Targeting Therapy Market Drivers
Figure 14-2: Challenges for Global BCMA Targeting Therapy Market
Figure 14-3: US - Annual Cost Comparison of BCMA Targeting Therapy with other Treatments (US$), September'2021


Companies Mentioned
. Allogene Therapeutics
. AbbVie
. Amgen
. BioTherapeutics
. Bluebird Bio
. Bristol Mayer Squibb
. Carsgen Therapeutics
. Celgene
. Cogent Bioscience
. CRISPR Therapeutics
. GlaxoSmithKline
. Harpoon Therapeutics
. Hrain Biotechnology
. iCell Gene Therapeutics
. Johnson & Johnson
. Juno Therapeutics
. Novartis
. Poseida Therapeutics
. Seagen
. Seattle Genetics